CPRX

PropThink: Catalyst Licenses New Candidate Ahead of November Data Release

[ACN Newswire] – By Jake KingCatalyst Pharmaceutical Partners (NASDAQ:CPRX) climbed as much as 18% ahead of the bell Wednesday after the company announced that it licensed the rights to an orphan drug for Lambert-Eaton … moreView todays social media effects on CPRXView the latest stocks trending across Twitter. Click to view dashboard […]

PropThink: Data Delay Offers a Second Chance at Short-Term Gains from CPRX

[ACN Newswire] – By Jake KingWednesday morning, Catalyst Pharmaceutical Partners (NASDAQ:CPRX) announced that its previous guidance for top-line trial data at the end of September would be delayed until November. Shares … moreView todays social media effects on CPRXView the latest stocks trending across Twitter. Click to view dashboard […]